The impact of ascending aorta dilatation on transcatheter aortic valve implantation outcomes

The impact of ascending aorta dilatation on transcatheter aortic valve implantation outcomes

The impact of ascending aorta dilatation (AAD) on transcatheter aortic valve implantation (TAVI) outcomes, compared to non-AAD, remains unclear. This meta-analysis aims to compare the outcomes of TAVI between patients with and without AAD. We systematically searched PubMed, ScienceDirect, Web of Sci...

Full description

Saved in:
Bibliographic Details
Main Authors: Pandit Bagus Tri Saputra, Wynne Widiarti, Ali Mustofa, Cornelia Ghea Savitri, Johanes Nugroho Eko Putranto, Faisal Yusuf Ashari, Chaq El Chaq Zamzam Multazam, Firas Farisi Alkaff, Mario D’Oria
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:International Journal of Cardiology: Heart & Vasculature
Subjects:
Ascending aortic dilatation
Complication
Mortality
Safety
Transcatheter aortic valve implantation
Cardiovascular disease
Online Access:http://www.sciencedirect.com/science/article/pii/S2352906725000831
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The impact of ascending aorta dilatation (AAD) on transcatheter aortic valve implantation (TAVI) outcomes, compared to non-AAD, remains unclear. This meta-analysis aims to compare the outcomes of TAVI between patients with and without AAD. We systematically searched PubMed, ScienceDirect, Web of Science, Springer, Cochrane, and Clinicaltrials.gov. for articles up to 25 March 2024 (PROSPERO ID CRD42024526311). A total of 204,078 patients from ten studies were included. Paravalvular regurgitation (RR 1.56 95 %CI: 1.32–1.84, p < 0.00001, I2 = 0 %) and aortic dissection (RR 3.55 95 %CI: 1.79–7.06, p = 0.0003, I2 = 40 %) were more common in AAD group. However, there were no differences in peri-procedural (RR 1.09, 95 %CI: 0.83–1.42, p = 0.53, I2 = 0 %) and 1-year (RR 0.79, 95 %CI: 0.51–1.23, p = 0.30, I2 = 0 %) mortality. Three-years (RR 0.88, 95 %CI: 0.54–1.44, p = 0.62) and five-years (RR 0.85, 95 %CI: 0.45–1.6, p = 0.61) follow-up showed comparable mortality between both groups. The other complications and the need for second valve implantation (RR 1.24, 95 %CI: 0.70–20.20, p = 0.48, I2 = 65 %) were similar between both groups. Despite the higher incidence of aortic dissection and paravalvular regurgitation in AAD than in non-AAD patients, these complications were not associated with worse short-term or long-term mortality. Therefore, TAVI remains a safe and effective option for AAD patients.
ISSN:2352-9067

Similar Items